

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number  
WO 2004/002497 A1

(51) International Patent Classification: A61K 31/706,  
A61P 15/04, 15/18, 17/12, 31/00, 35/00, G01N 33/58

(74) Agent: WRAY & ASSOCIATES; Level 4, The Quadrant,  
1 Williams Street, Perth, Western Australia 6000 (AU).

(21) International Application Number:  
PCT/AU2003/000788

(22) International Filing Date: 24 June 2003 (24.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PS 3290 1 July 2002 (01.07.2002) AU

(71) Applicant (for all designated States except US): SOLBEC  
PHARMACEUTICALS LIMITED [AU/AU]; Level 1,  
10 Stirling Highway, Nedlands, Western Australia 6009  
(AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARTER, Stephen,  
John [AU/AU]; 8 Baybury Rise, Woodvale, Western  
Australia 6026 (AU). WILLIAMS, Elizabeth [AU/AU];  
5 Craig Street, Wembley Downs, Western Australia 6019  
(AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW);  
Burasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM);  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR); OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GLYCOALKALOID COMPOSITIONS AND VARIOUS USES THEREOF



(57) Abstract: A composition comprising at least two glycoalkaloids of formula (I): wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V): or each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>; each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>; each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising -CH<sub>2</sub>-, -O- and -NH<sub>2</sub>-; and wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptiose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

WO 2004/002497 A1

WO 2004/002497

PCT/AU2003/000788

## "Glycoalkaloid Compositions and Various Uses Thereof."

### Field of the Invention

The present invention relates to compositions including glycoalkaloids such as solasonine and solamargine, to pharmaceutical compositions including glycoalkaloids and to methods of treating various disorders such as cancer and psoriasis with the compositions.

### Background Art


BEC® is a therapeutic agent comprising a mixture of the triglycosides: solasonine and solamargine, their corresponding mono and diglycosides, solasodine (an aglycone) and free sugars.

It has previously been recognised that the free sugars in BEC® may reduce its therapeutic activity. However, no studies have been carried out to determine what constituents in BEC® may be used in combination to treat cancer and/or the preferred ratios of any such constituents.

15 The present invention seeks to overcome or at least partially alleviate this problem.

### Summary of the Invention

The present invention provides a composition comprising at least two glycoalkaloids of formula I:




WO 2004/002497

PCT/AU2003/000788

- 2 -

wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



5

each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ;

- 10 each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

"X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

- wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladino-
- 15
- 20

WO 2004/002497

PCT/AU2003/000788

- 3 -

been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $\text{CH}_2\text{OH}$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and

wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso  
5 that (i) when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated; or (ii) when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

The present invention also provides a composition consisting essentially of at  
10 least two glycoalkaloids of formula I wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V); each of  $\text{R}^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $\text{OR}^4$ ; each of  $\text{R}^2$  is a radical separately  
15 selected from the group consisting of hydrogen, amino and  $\text{OR}^4$ ; each of  $\text{R}^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising  $-\text{CH}_2-$ ,  $-\text{O}-$  and  $-\text{NH}_2-$ ; and wherein the compound includes at least one  $\text{R}^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising  
20 glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose,  
25 cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $\text{CH}_2\text{OH}$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates.

The present invention also provides a pharmaceutical composition comprising a  
30 glycoalkaloid composition of the present invention and a pharmaceutically acceptable carrier.

WO 2004/002497

PCT/AU2003/000788

- 4 -

The present invention also provides a method of treating cancer comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a cancer patient.

5 The present invention also provides a method of treating psoriasis comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a psoriasis patient.

10 The present invention also provides a method for contraception comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a subject to at least reduce and preferably totally remove the subjects ability to fall pregnant.

The present invention also provides a method of terminating a pregnancy comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a pregnant subject.

15 The present invention also provides a method of treating a subject infected with a pathogenic organism comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to the infected subject.

20 The present invention also provides a method of treating abnormal cell growth in a patient comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a patient with abnormal cell growth.

25 The present invention also provides a method of diagnosing or identifying abnormal cell growth in a subject comprising the step of applying a composition or pharmaceutical composition of the present invention to a test area on said subject and then monitoring said test area for inflammation.

The present invention also provides a method of diagnosing or identifying abnormal cell growth in a subject comprising the step of administering a

WO 2004/002497

PCT/AU2003/000788

- 5 -

composition or pharmaceutical composition of the present invention, incorporating a detectable label, to a subject and then detecting said label.

### Brief Description of the Drawings


Figures 1A-1C depict the results of cell assays assessing the activity of various ratios of solamargine and solasonine in the cell lines NHDF-Ad, 786-0 and NO36, respectively.

Figures 2A and 2B are photographs depicting a human patient with psoriasis in the elbow region before (2A) and after (2B) treatment with a cream containing 0.1% of a 1:1 ratio of solasonine and solamargine.

### 10 Detailed Description of the Invention

#### Glycoalkaloid compositions

The present invention provides a composition comprising at least two glycoalkaloids of formula I:






15 wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):


WO 2004/002497

PCT/AU2003/000788

- 6 -



or



each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ;

each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ;

each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

"X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;



WO 2004/002497

PCT/AU2003/000788

- 7 -

wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

Throughout the specification, unless the context requires otherwise, the word  
5 "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

For the purposes of the present invention the term "isolated" means essentially free of (i) mono and diglycosides and, preferably, essentially free of (ii) free  
10 sugars such as mono, di, tri, oligo or polysaccharides and (iii) aglycone. However, unless steps are taken to stabilise the glycoalkaloids, it will be appreciated that even in an isolated glycoalkaloid composition of the present invention there will be a small amount of free sugars and mono and diglycosides that result from degradation of the glycoalkaloids.

15 The number of glycoalkaloids in the composition may be varied, as may their relative ratios in the composition. However, when the composition comprises two glycoalkaloids they may be present in a ratio selected from the group of ratios consisting of approximately: 1:6 - 1:0.5; 1:5; 1:4; 1:3; 1:2, 1:1.5 and 1:1. In this regard, surprisingly, it has been found that compositions containing particular  
20 ratios of glycoalkaloids have a potentiated activity relative to (i) compositions containing the individual glycoalkaloids and (ii) BEC®.

The glycoalkaloids of the present invention may be varied. Preferably, the glycoalkaloids are triglycoside glycoalkaloids, solasodine glycosides or are selected from the group of glycoalkaloids consisting of: solamargine, solasonine,  
25 solanine, tomatine, solanocapsine and 26-aminofurostane.

The glycoalkaloids of the present invention may be chiral, stereoisomers and mixtures thereof including enantiomers and/or diastereoisomers. Furthermore, the glycoalkaloids of the present invention may be isolated from natural sources, synthesized or produced by chemically modifying other glycoalkaloids.

WO 2004/002497

PCT/AU2003/000788

- 8 -

The present invention also provides a composition comprising solamargine and solasonine in a ratio between about 1:6 and 6:1 on the proviso that when the solamargine and solasonine are present in a 1:1 ratio the solamargine and solasonine are isolated. Preferably, the solamargine:solasonine ratio is between about 1:4 and 4:1, 1:3 and 3:1 or 1:2 to 2:1.

Thus, the present invention also provides a composition comprising about a 1:1 ratio of solamargine and solasonine in isolated form.

The present invention also provides a composition comprising at least two glycoalkaloids of formula I wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V); each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>; each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>; each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising -CH<sub>2</sub>-, -O- and -NH<sub>2</sub>-; and wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

WO 2004/002497

PCT/AU2003/000788

- 9 -

Preferably, the glycoalkaloids are triglycoside alkaloids and constitute greater than 70%-90% of the glycosides in the composition, more preferably 91-95% and even more preferably 96-100% of the glycosides in the composition.

5 The number of glycoalkaloids in the composition may be varied, as may their relative ratios in the composition. However, when the composition comprises two glycoalkaloids they may be present in a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

Preferably, the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

Particularly preferred glycoalkaloids are solasodine glycosides such as solamargine and solasonine. Thus, the present invention also provides a composition comprising solamargine and solasonine in a ratio between about 1:6 and 6:1, 1:4 and 4:1, 1:3 and 3:1 or 1:2 to 2:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

One particular composition of the present invention comprises about a 1:1 ratio of solamargine and solasonine on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

20 The present invention also provides a composition consisting essentially of at least two glycoalkaloids of formula I wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V); each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>; each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>; each of R<sup>3</sup> is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising -CH<sub>2</sub>-, -O- and -NH<sub>2</sub>-; and wherein the compound includes at least one R<sup>4</sup> group that is a carbohydrate or a derivative thereof selected from the group comprising

WO 2004/002497

PCT/AU2003/000788

- 10 -

glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses; heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH<sub>2</sub>OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates.

10 For the purposes of the present invention the phrase "consisting essentially of" means that the glycoalkaloids in the composition are the only glycosides therein. Thus, a composition consisting essentially of solamargine and solasonine includes solamargine and solasonine and may include other non-glycoside constituents.

15 Preferably, the glycoalkaloids are triglycoside alkaloids and constitute greater than 70%-90% of the glycosides in the composition, more preferably 91-95% and even more preferably 96-100% of the glycosides in the composition.

The number of glycoalkaloids in the composition may be varied, as may their relative ratios in the composition. However, when the composition consists essentially of two glycoalkaloids they may be present in a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

Preferably, the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

25 Particularly preferred glycoalkaloids are solasodine glycosides such as solamargine and solasonine. Thus, the present invention also provides a composition consisting essentially of solamargine and solasonine in a ratio between about 1:6 and 6:1, 1:4 and 4:1, 1:3 and 3:1 or 1:2 to 2:1. One particular

WO 2004/002497

PCT/AU2003/000788

- 11 -

composition of the present invention consists essentially of about a 1:1 ratio of solamargine and solasonine.

The amount of glycoalkaloids in the compositions of the present invention may be varied depending on their intended end use. Preferably, the compositions  
5 comprise about 0.001% - 5% or 10% glycoalkaloids, more preferably 0.01% - 5% or 10% and even more preferably 0.1%- 5% or 10% glycoalkaloids.

#### Pharmaceutical compositions

The compositions of the present invention may be capable of administration to a patient to treat a disorder. Thus, the present invention also provides a  
10 pharmaceutical composition comprising a glycoalkaloid composition of the present invention and a pharmaceutically acceptable carrier.

Methods for the preparation of pharmaceutical compositions comprising one or more active ingredients are generally known in the art. Such pharmaceutical compositions will generally be formulated for the mode of delivery that is to be  
15 used and will usually include one or more pharmaceutically acceptable carriers. A "pharmaceutically acceptable carrier" is a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the glycoalkaloid composition without causing unacceptable biological effects or interacting in a deleterious manner with any of the other components of the  
20 pharmaceutical composition in which it is contained.

Thus, in addition to the glycoalkaloid composition and aforementioned additives, pharmaceutical compositions of the invention may further comprise suitable carriers, excipient and diluents that are pharmaceutically acceptable and compatible with the active ingredient. Some examples of suitable carriers,  
25 excipient and diluents include, without limitation, water, saline, ethanol, dextrose, cyclodextrins such as hydroxy propyl beta-cyclodextrin, glycerol, lactose, dextrose, sucrose sorbitol, mannitol, starches, gum acacia, calcium phosphates, alginate, tragacanth, gelatine, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and

WO 2004/002497

PCT/AU2003/000788

- 12 -

propylhydroxybenzoates, talc, magnesium stearate and mineral oil or combinations thereof.

The formulations can additionally include lubricating agents, pH buffering agents, wetting agents, emulsifying and suspending agents, preserving agents, 5 sweetening agents or flavouring agents. The particular selection of constituent that can be included in the compositions described herein will generally depend on the particular mode of delivery used to bring the glycoalkaloid into contact with the target cells or tissue.

Pharmaceutical compositions according to the invention may be administered to a 10 patient using any technology or delivery route that permits contact between the glycoalkaloid and the target cell or tissue. Preferably, the composition is administered by topical or oral means. However, any technology that allows targeted delivery of the pharmaceutical composition via, intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, 15 intracranially, intracapsularly, intraspinally, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally or by pulmonary administration may be used to deliver the composition to a tumorous growth. Suitable dosage forms include for example, pastes, gels, liquids, tablets, troches, dispersions, suspensions, solutions, capsules, patches, suppositories and the like, although 20 oral dosage forms are preferred.

The mode of administration must, however, be at least suitable for the form in which the composition has been prepared. The mode of administration for the most effective response may need to be determined empirically and the means of administration described below are given as examples and do not limit the method 25 of delivery of the composition of the present invention in any way. All the formulations described below are commonly used in the pharmaceutical industry and are commonly known to suitably qualified practitioners.

#### **(a) Topical delivery**

Various topical delivery systems may be appropriate for administering the 30 compositions of the present invention depending upon the preferred treatment

WO 2004/002497

PCT/AU2003/000788

- 13 -

regimen. Topical formulations may be produced by dissolving or combining the glycoalkaloid composition of the present invention in an aqueous or nonaqueous carrier. In general, any liquid, cream, or gel, or similar substance that does not appreciably react with the glycoalkaloid or any other of the active ingredients that  
5 may be introduced into the composition and which is non-irritating is suitable. Appropriate non-sprayable viscous, semi-solid or solid forms can also be employed that include a carrier compatible with topical application and have a dynamic viscosity preferably greater than water.

Suitable formulations are well known to those skilled in the art and include, but are  
10 not limited to, solutions, suspensions, emulsions, creams, gels, ointments, powders, liniments, salves, aerosols, transdermal patches, etc, which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, emulsifiers, wetting agents, fragrances, colouring agents, odour controllers, thickeners such as natural gums etc. Particularly preferred topical formulations  
15 include ointments, creams or gels.

Ointments generally are prepared using either (1) an oleaginous base, i.e., one consisting of fixed oils or hydrocarbons, such as white petroleum or mineral oil, or (2) an absorbent base, i.e., one consisting of an anhydrous substance or substances which can absorb water, for example anhydrous lanolin. Customarily,  
20 following formation of the base, whether oleaginous or absorbent, the glycoalkaloid is added to an amount affording the desired concentration.

Creams are oil/water emulsions. They consist of an oil phase (internal phase), comprising typically fixed oils, hydrocarbons and the like, waxes, petroleum, mineral oil and the like and an aqueous phase (continuous phase), comprising  
25 water and any water-soluble substances, such as added salts. The two phases are stabilised by use of an emulsifying agent, for example, a surface active agent, such as sodium lauryl sulfate; hydrophilic colloids, such as acacia colloidal clays, veegum and the like. Upon formation of the emulsion, the glycoalkaloid composition is customarily added in an amount to achieve the desired  
30 concentration.

WO 2004/002497

PCT/AU2003/000788

- 14 -

Gels comprise a base selected from an oleaginous base, water, or an emulsion-suspension base. To the base is added a gelling agent that forms a matrix in the base, increasing its viscosity. Examples of gelling agents are hydroxypropyl cellulose, acrylic acid polymers and the like. Customarily, the glycoalkaloid composition is added to the formulation at the desired concentration at a point preceding addition of the gelling agent.

The amount of the glycoalkaloid compound incorporated into a topical formulation is not critical; the concentration should be within a range sufficient to permit ready application of the formulation to the affected tissue area in an amount that will deliver the desired amount of glycoalkaloid to the desired treatment site.

The customary amount of a topical formulation to be applied to an affected tissue will depend upon an affected tissue size and concentration of the glycoalkaloid in the formulation.

#### (b) Oral Delivery

The pharmaceutical compositions of the present invention may also be adapted for oral administration in such a manner that facilitates delivery of a therapeutically effective concentration of the glycoalkaloid to the target cell or tissue.

The effective dosages of the glycoalkaloid, when administered orally, must take into consideration the diluent, preferably water. The composition preferably contains about 1 to about 200mg glycoalkaloid. When the compositions are ingested, desirably they are taken on an empty stomach.

Contemplated for use herein are oral solid dosage forms, which are described generally in *Martin, Remington's Pharmaceutical Sciences*, 18th Ed. (1990 Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatised with various polymers (e.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given



WO 2004/002497

PCT/AU2003/000788

- 15 -

by Marshall, in *Modern Pharmaceutics*, Chapter 10, Banker and Rhodes ed., (1979), herein incorporated by reference. In general, the formulation will include the glycoalkaloid composition described as part of the invention and inert ingredients that allow for protection against the stomach environment and release of the glycoalkaloid in the intestine.

In some instances it may be desirable that a pharmaceutical composition of the invention release the glycoalkaloid in the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations that will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the composition or by release of the glycoalkaloid beyond the stomach environment, such as in the intestine.

To ensure full gastric resistance, a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S and Shellac. These coatings may be used as mixed films.

A coating or mixture of coatings that are not intended for protection against the stomach can also be used on tablets. This can include sugar coatings, or coatings that make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatine) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatine shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, moulded tablets or tablet triturates, moist massing techniques can be used.

Colourants and flavoring agents may all be included. For example, glycoalkaloid compositions may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavouring agents.

WO 2004/002497

PCT/AU2003/000788

- 16 -

One may dilute or increase the volume of the glycoalkaloid composition with an inert material. These diluents could include carbohydrates, especially mannitol, alpha-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

Disintegrants may be included in the pharmaceutical formulations of the present invention. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatine, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Other disintegrants include insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

Binders may be used to hold the pharmaceutical composition together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatine. Others include methylcellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

An antifrictional agent may be included in the glycoalkaloid composition to prevent sticking during the formulation process. Lubricants may be used as a layer between the glycoalkaloid and the die wall and these can include but are not limited to: stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights and Carbowax 4000 and 6000.

Glidants that might improve the flow properties of the composition during fomulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

WO 2004/002497

PCT/AU2003/000788

- 17 -

To aid dissolution of the glycoalkaloid into the aqueous environment, a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the pharmaceutical composition as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the composition either alone or as a mixture in different ratios.

Additives, which potentially enhance uptake of the glycoalkaloids, are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

Controlled release formulations may be desirable. The compositions could be incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms i.e., gums. Slowly degenerating matrices may also be incorporated into the pharmaceutical composition. Another form of a controlled release is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the composition is enclosed in a semipermeable membrane which allows water to enter and push the composition out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidised bed or by compression coating.

The glycoalkaloid can be included in the pharmaceutical composition as fine multiparticulates in the form of granules or pellets of particle size about 1mm. The formulation of the glycoalkaloid for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The glycoalkaloid could be prepared by compression.

Thus, the invention further provides for compositions of microparticles, created from hydrophilic polymers, which contain the glycoalkaloid. The microparticles containing the glycoalkaloid composition may be made by a variety of methods

WO 2004/002497

PCT/AU2003/000788

- 18 -

known to those in the art, for example, solvent evaporation, desolvation, complex coacervation, polymer/polymer incompatibility, interfacial polymerisation etc.

In a preferred embodiment of the invention, the hydrophilic polymers forming the microparticles are attached to a targeting protein that acts to enable the  
5 microparticle/glycoalkaloid complex to specifically bind selected target cells or tissues bearing the target molecule (e.g. characteristic marker).

In a more preferred embodiment, the hydrophilic polymers are conjugated to the Fab' fragment of an antibody. Smaller peptides from the hypervariable region or from another peptide interacting with a specific cell surface ligand may also be  
10 conjugated to the complexes. It is most preferred that the antibodies or antibody fragments are directed against target molecules associated with cancerous tissues or cells.

It will be appreciated that the targeting protein (e.g. an antibody or an antibody fragment) can be attached to the hydrophilic polymers either before or after  
15 formation of the microparticle/glycoalkaloid complex. In a preferred embodiment, the targeting protein is coupled to the hydrophilic polymer, where the targeting protein/hydrophilic polymer is subsequently used to form the microparticle/glycoalkaloid complex. This provides a convenient means for modifying the targeting specificity of an otherwise generic microparticle.

20 Targeted microparticles may be prepared by incorporating the Fab' fragment into the microparticles by a variety of techniques well known to those of skill in the art. For example, a biotin conjugated Fab' may be bound to a microparticle containing a streptavidin. Alternatively, the biotinylated Fab' may be conjugated to a biotin derivatised microparticle by an avidin or streptavidin linker. Typically about 30 to  
25 125 and more typically about 50 to 100 Fab' fragments per microparticle/glycoalkaloid complex are used.

WO 2004/002497

PCT/AU2003/000788

- 19 -

The pharmaceutical compositions of the present invention may also be formed into powders or some other form that is suitable for delivery by inhalation. Whilst inhalation may be via the mouth it will be appreciated that the route of delivery may also be via the nose.

- 5 These compositions are particularly useful for treatment of diseases or disorders of the respiratory system such as lung cancer or cancer that may affect other parts of the respiratory system. When designing compositions for delivery to the lungs, they are preferably designed to reach the site of the alveoli.

- Persons skilled in the art will have all the skills and information necessary to  
10 prepare such compositions as a routine exercise. When the compositions are adapted for delivery by inhalation they may contain various doses of active agent and the particular dose will be determined by a skilled practitioner with due consideration to the recipient and the state of the disease to be treated. However, preferably, the compositions contain between about 100ug-100mg of  
15 glycolalkaloids, about 200ug-50mg of glycoalkaloids or 200ug – 10mg glycoalkaloids.

### (c) Parenteral delivery

- The pharmaceutical compositions of the present invention may also be adapted for parenteral administration that facilitates delivery of a therapeutically effective  
20 amount of glycoalkaloid to the target cell or tissue.

- Pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. Alternatively, the glycoalkaloids may be encapsulated in liposomes and delivered in injectable  
25 solutions to assist their transport across cell membrane. The solution may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol and the like), suitable mixtures thereof and vegetable oils or cyclodextrins such as hydroxy propyl beta-cyclodextrin. Proper fluidity may be maintained, for example, by the  
30 use of a coating such as lecithin, by the maintenance of the required particle size

WO 2004/002497

PCT/AU2003/000788

- 20 -

in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatine.

- 5 Sterile injectable solutions may be prepared by incorporating the glycoalkaloids in the required amount in an appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle that contains the basic dispersion medium and the required
- 10 other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying techniques that yield a powder of the active ingredient plus, optionally, any additional desired ingredient from previously sterile-filtered solution thereof.

15 Methods of Treatment/Diagnostics

The present invention also provides a method of treating cancer comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a cancer patient.

- The present invention also provides a method of treating psoriasis comprising the
- 20 step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a psoriasis patient.

- The present invention also provides a method for contraception comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a subject to at least reduce and preferably
- 25 totally remove the subjects ability to fall pregnant.

The present invention also provides a method for killing sperm comprising the step of contacting said sperm with an effective amount of a composition or pharmaceutical composition of the present invention.

WO 2004/002497

PCT/AU2003/000788

- 21 -

The present invention also provides a method of terminating a pregnancy comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to a pregnant subject.

5 The present invention also provides a method of treating a subject infected with a pathogenic organism comprising the step of administering an effective amount of a composition or pharmaceutical composition of the present invention to the infected subject.

The present invention also provides a method of treating or abnormal cell growth in a patient comprising the step of administering an effective amount of a  
10 composition or pharmaceutical composition of the present invention to a patient with abnormal cell growth.

The present invention also provides a method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition or pharmaceutical composition of the present invention to a test area on said subject and then  
15 monitoring said test area for inflammation.

This diagnostic may be used to diagnose skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas. Preferably the abnormal cell growth is located on the skin of the subject.

Other diagnostic methods according to the present invention involve the use of a  
20 composition of the present invention further comprising a detectable label. In this regard, the ability of the constituents of the compositions of the present invention to bind to and gain entry to target cells (cancer cells and other cells displaying abnormal growth) renders them particularly adapted to be combined with a detectable label that can also become associated with a target cell. Once  
25 associated the label can then be detected to arrive at a diagnosis.

The particular choice of label and associated detection system may be varied as required and any one of a number of options would be apparent to those skilled in

WO 2004/002497

PCT/AU2003/000788

- 22 -

the art. Examples include radioactive labels/detection systems and the use of labels that are readily visualised under x-ray.

Labels include radio-opaque or other compounds that can be visualised with X-rays, CAT-scans, or MRI. When interpreting the resulting patterns account must  
5 be taken on background signal or "noise" from non-cancer cells that also bear the label, albeit at lower levels. However, those skilled in the art are readily able to discern noise from actual signal in performing the diagnosis.

Other labels include fluorescent labels that can be detected with light microscopic, flow cytometric, or fluorometric detection or histologically using immunoelectron  
10 microscopy or non-immuno assays, for in situ detection.

In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labelled composition of the present invention. The labelled composition is preferably applied by overlaying it onto a biological sample. Through the use of such a procedure, it is possible to determine not only  
15 the presence of the target cells but also their distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

Immunoassays and non-immunoassays using the compositions of the present  
20 invention will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells with the labelled composition and detecting the label by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and immobilized onto a  
25 solid phase support or carrier such as nitrocellulose, or other solid support that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the labelled compositions. The solid phase support may then be washed with the buffer a



WO 2004/002497

PCT/AU2003/000788

- 23 -

second time to remove unbound composition. The amount of bound label on solid support may then be detected by conventional means.

Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to a labelled composition of the present invention. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers or will be able to ascertain the same by use of routine experimentation.

The compositions of the present invention can also be detectably labelled by linking the same to an enzyme. This then renders the composition suitable for use in an enzyme immunoassay (EIA). The enzyme that is bound to the composition will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to detectably label the composition include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alphas-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by calorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

WO 2004/002497

PCT/AU2003/000788

- 24 -

Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labelling the compositions, it is possible to detect the labelled cells through the use of a radioimmunoassay (RIA). The radioactive isotope can be detected by such means as the use of a gamma  
5 counter or a scintillation counter or by autoradiography.

It is also possible to label the compositions with a fluorescent compound. When the fluorescently labelled compositions are exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate,  
10 rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

Compositions can also be detectably labelled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the glycoalkaloids in the composition using metal chelating groups such as  
15 diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The compositions can also be detectably labelled by coupling the glycoalkaloids therein to a chemiluminescent compound. The presence of the chemiluminescent-tagged entity is then determined by detecting the presence of  
20 luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labelling compounds are luminol, isoluminol, therromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the compositions of the present invention. Bioluminescence is a type of chemiluminescence found in  
25 biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labelling are luciferin, luciferase and aequorin.

WO 2004/002497

PCT/AU2003/000788

- 25 -

As an alternative to the methods of treatment and diagnosis involving the use of the compositions and pharmaceutical compositions of the present invention that comprise a plurality of glycoalkaloids, it will be appreciated that the methods herein may also comprise administration of the plurality of glycoalkaloids as  
5 separate formulations.

When the plurality of glycoalkaloids is administered as separate formulations they are preferably administered in a manner that mimics the delivery of a single formulation containing the glycoalkaloids. Thus, they may be administered simultaneously or in any other fashion that enables the glycoalkaloids to reach the  
10 target site simultaneously and achieve their therapeutic effect.

The present invention will now be described with reference to a number of examples. The examples are in no way limiting on the preceding description.

### Examples

**Example 1: Relative activity of solamargine and solasonine when used in  
15 combination**

#### Materials/Methods

Tumour cell lines A2058, NO36 and LS174T and the normal adult dermal fibroblast line NHDF-Ad were used in 5000 cell, six day assays to compare dose per cell at LD<sub>50</sub> values for BEC (1:1 solamargine:solasonine), solamargine,  
20 solasonine and an equimolar mixture of solamargine and solasonine. Data from the fibroblast cell line NHRE in a 2500 cell 3 day assay was also obtained.

Tumour cell line LNCaP was used at 7500 cells in a six day assay format while 786-O was used in a 650 cell, six day format where dose per cell is not a limiting factor determining LD<sub>50</sub> as well as in 5000 cell, three day format where dose per  
25 cell does limit LD<sub>50</sub>.

WO 2004/002497

PCT/AU2003/000788

- 26 -

**Results**

The results are set out hereunder in Table 1.

Table 1 Comparison of *in vitro* activity

Dose per cell at LD <sub>50</sub> , pg/cell of total alkaloid (Dose per cell limiting)				
Cell Line	BEC	Solamargine	Solasonine	Solamargine and Solasonine (1:1)
NO36	298.0	154.8	613.2	148.4
LNCaP	428.5	121.9	432.5	117.3
LS174T	465.2	162.8	>400	171.6
A2058	247.0	199.0	685	78
786-O	321.2	208.0	>400	134.4
NHDF-Ad <sup>A</sup>	287.8	209.2	587.6	128
NHRE <sup>A</sup>	344.7	227.9	1657.7	289.2
Dose per cell at LD <sub>50</sub> , pg/cell of total alkaloid (Dose per cell not limiting)				
786-O	1354.0	1394.0	5606.0	452.3

A - normal cells

- 5 Values reported as >400 reflect data sets in which the range of solasonine concentrations used were sub optimal for data fitting to obtain a reliable, precise value of LD<sub>50</sub>.

**Example 2: Effect of solamargine:solasonine ratio on activity**

**Materials/Methods**

- 10 Tumour cell lines 786-O and NO36 and normal fibroblasts NHDF-Ad were used in 5000 cell assays, for three, six and six day assays, respectively, to study the effect of solamargine:solasonine ratio on cytotoxicity.

WO 2004/002497

PCT/AU2003/000788

- 27 -

Solutions of 4mg/mL solamargine and 4mg/mL solasonine in 3% acetic acid were mixed to provide the various ratios. These mixtures were diluted in the culture medium appropriate to the cell line used to concentrations ranging from 0.32 to 40 ug/mL. Fifty uL aliquots were added to tissue culture wells seeded with 5000 cells in 150uL culture medium 24 hours previously.

Cell survival was assessed using the MTT cell proliferation assay following four days growth after application of the alkaloids. The formazan absorbance of alkaloid treated wells relative to wells treated with an equivalently dilute acetic acid solution expressed as a percentage has been taken as percentage cell survival.

### Results

The results are set out in Table 2 hereunder.

Table 2 – Effect of solamargine:solasonine ratios on activity

Solamargine (%)	Dose per cell at LD <sub>50</sub> , (pg)		
	786-O, 3 day assay	NO36, 6 day assay	NHDF-Ad, 6 day assay
100	304	209	112
75	410	161	176
66.7	234	155	96
50	160	157	128
33.3	236	191	176
25	334	198	224
0	500	613	400

The results in the above table are graphically represented in Figures 1A-1C.

WO 2004/002497

PCT/AU2003/000788

- 28 -

**Example 3: Treatment of psoriasis****Materials/Methods**

A cream containing 0.1% of solasonine and solamargine in a 1:1 ratio was used in this study.

- 5 A man with long term and persistent psoriasis was administered a composition of the present invention by applying the above cream to the affected area on a daily basis for three weeks.

**Results**

- The results are depicted in Figures 2A and 2B, which show the affected area of  
10 the subject before (2A) and after (2B) treatment with the cream.

The present invention includes modifications and adaptations apparent to one skilled in the art.

- Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to  
15 imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.


WO 2004/002497

PCT/AU2003/000788

- 29 -




**The Claims Defining the Invention are as Follows**

1. A composition comprising at least two glycoalkaloids of formula I:




wherein: either one or both of the dotted lines represents a double bond,  
and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



or



each of R<sup>1</sup> is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR<sup>4</sup>;

each of R<sup>2</sup> is a radical separately selected from the group consisting of hydrogen, amino and OR<sup>4</sup>;

WO 2004/002497

PCT/AU2003/000788

- 30 -

each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;

"X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

5 wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose,  
10 fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar  
15 alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;

wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

- 20 2. A composition according to claim 1 comprising two glycoalkaloids in a ratio selected from the group of ratios consisting of approximately: 1:6 - 1:0.5; 1:5; 1:4; 1:3; 1:2, 1:1.5 and 1:1.
3. A composition according to claim 1 or 2 wherein the glycoalkaloids are triglycoside glycoalkaloids or solasodine glycosides.
- 25 4. A composition according to any one of claims 1 to 3 wherein the glycoalkaloids are selected from the group consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.



WO 2004/002497

PCT/AU2003/000788

- 31 -

5. A composition comprising about a 1:1 ratio of solamargine and solasonine in isolated form.

6. A composition comprising at least two glycoalkaloids of formula I wherein:

5 either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V);

10 each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ; each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ; each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

15 wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, 20 nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoses), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, 25 saccharinic acids, sugar phosphates; and

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

WO 2004/002497

PCT/AU2003/000788

- 32 -

7. A composition according to claim 6 wherein the glycoalkaloids are triglycoside alkaloids and constitute at least 70%-90% of the glycosides in the composition.
8. A composition according to claim 6, wherein the glycoalkaloids are triglycoside alkaloids and constitute at least 91-95% of the glycosides in the composition.
- 5 9. A composition according to claim 6, wherein the glycoalkaloids are triglycoside alkaloids and constitute at least 96-100% of the glycosides in the composition.
10. A composition according to any one of claims 6 to 9 comprising two glycoalkaloids in a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.
- 10 11. A composition according to any one of claims 6 to 10 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.
12. A composition comprising solamargine and solasonine in a ratio between  
15 about 1:6 and 6:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.
13. A composition comprising solamargine and solasonine in a ratio between about 1:4 and 4:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.
- 20 14. A composition comprising solamargine and solasonine in a ratio between about 1:3 and 3:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.
15. A composition comprising solamargine and solasonine in a ratio between about 1:2 and 2:1 on the proviso that the solasonine and solamargine do not  
25 constitute 66% of the glycosides in the composition.

WO 2004/002497

PCT/AU2003/000788

- 33 -

16. A composition comprising a 1:1 ratio of solamargine and solasonine on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

17. A composition consisting essentially of at least two glycoalkaloids of formula I  
5 wherein:

either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

10 A: represents a radical selected from the following radicals of general formulae (II) to (V); each of  $R^1$  is a radical separately selected from the group consisting of hydrogen, amino, oxo and  $OR^4$ ; each of  $R^2$  is a radical separately selected from the group consisting of hydrogen, amino and  $OR^4$ ; each of  $R^3$  is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising  $-CH_2-$ ,  $-O-$  and  $-NH_2-$ ; and

15 wherein the compound includes at least one  $R^4$  group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose,  
20 fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinoise), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of  $CH_2OH$ ), sugar  
25 alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates.

18. A composition according to claim 17 wherein the glycoalkaloids are triglycoside alkaloids and constitute at least 70%-90% of the glycosides in the composition.

WO 2004/002497

PCT/AU2003/000788

- 34 -

19.A composition according to claim 17 wherein the glycoalkaloids are triglycoside alkaloids and constitute at least 91-95% of the glycosides in the composition.

20.A composition according to claim 17 wherein the glycoalkaloids are  
5 triglycoside alkaloids and constitute at least 96-100% of the glycosides in the composition.

21.A composition according to any one of claims 17 to 20 wherein the composition consists essentially of two glycoalkaloids in a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

10 22.A composition according to any one of claims 17 to 21 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

23.A composition consisting essentially of solamargine and solasonine in a ratio  
15 between about 1:6 and 6:1, 1:4 and 4:1, 1:3 and 3:1 or 1:2 to 2:1.

24.A composition consisting essentially of about a 1:1 ratio of solamargine and solasonine.

25.A composition according to any one of the preceding claims comprising about 0.001% - 5% glycoalkaloids.

20 26.A composition according to any one of the preceding claims comprising about 10% glycoalkaloids.

27.A pharmaceutical composition comprising a composition of any one of the preceding claims and a pharmaceutically acceptable carrier.

25 28.A pharmaceutical composition according to claim 27 adapted for topical delivery.

29.A pharmaceutical composition according to claim 27 adapted for oral delivery.

WO 2004/002497

PCT/AU2003/000788

- 35 -

30. A pharmaceutical composition according to claim 27 adapted for parenteral delivery.

31. A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition of any one of claims 1 to 5 26 or a pharmaceutical composition of any one of claims 27 to 30.

32. A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30.

33. A method of treating or abnormal cell growth in a patient comprising the step 10 of administering the patient an effective amount of a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30.

34. A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30 to a test area on said subject and 15 then monitoring said test area for inflammation.

35. A method according to claim 34 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

36. A method for achieving contraception in a subject comprising the step of 20 administering an effective amount of a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30 to the subject.

37. A method for killing sperm comprising the step of contacting said sperm with an effective amount of a composition of any one of claims 1 to 26 or a 25 pharmaceutical composition of any one of claims 27 to 30.

WO 2004/002497

PCT/AU2003/000788

- 36 -

38. A method of terminating a pregnancy in a subject comprising the step of administering the subject an effective amount of a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30.

5 39. A method of treating a subject infected with a pathogenic organism comprising the step of administering to the subject an effective amount of a composition of any one of claims 1 to 26 or a pharmaceutical composition of any one of claims 27 to 30.

40. A composition of any one of claims 1 to 26 further comprising a detectable label.

10 41. Use of a composition according to claim 40 for detecting a target cell comprising the steps of applying the composition to a sample or a subject and detecting the label.

WO 2004/002497

PCT/AU2003/000788

- 1/2 -




Figure 1A




Figure 1B




Figure 1C

WO 2004/002497

PCT/AU2003/000788

- 2/2 -



Figure 2A



Figure 2B



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU03/00788

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. <sup>7</sup>: A61K 31/706, A61P 15/04, 15/18, 17/12, 31/00, 35/00, G01N 33/58

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Chemical Abstracts CAPLUS, Medline: tomatine, solasonine, solamargine, solanocapsine, furostane

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AU 540812 B (57853/80) to Aruba (Qld.) Pty. Ltd (6 November 1980, See claims, examples.	1 - 41
Y	Cham, Bill E. et al, Planta medica Vol 53 (1) (1987) pp 34 -36. See the whole document, in particular see page 36.	1 - 41
Y	Cham, B. E. Drugs of the Future Vol 13 (8) (1988) pp 714 - 716. See the whole document.	1 - 41

☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
28 August 2003

Date of mailing of the international search report

04 SEPTEMBER 2003

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaustalia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer

K.G. ENGLAND

Telephone No : (02) 6283 2292

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00788

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Daunter, B et al, Cancer Letters, 55 (1990) pp209-220. See page 209 in particular.	1 - 41
Y	Cham, B. E. et al, Cancer Letters, Vol 59 (1991) pp183-192. See page 183 in particular.	1 - 41
Y	AU-654474-B (71549/91) to Cura Nominees Pty. Ltd. (5 August 1991). See pages 3 to 12 in particular.	1 - 41
Y	Ghosh, M. et al, Int. J. Pharmacognosy, Vol 32 (2) (1994) pp 184 - 190. See page 186 in particular.	39
Y	Li-Ching Chang et al, Biochem. Biophys. Research Communications, 242 pages 21-25 (1998). See page 21 and page 23, Figure 1 in particular.	1 - 41
Y	Cham B.E., Asia Pacific Journal of Pharmacology 1994, 9, pp113 - 118. See the whole document.	1 - 41
Y	AU 35454/00-A to Cura Nominees Pty. Ltd. (14 November 2000). See pages 6 to 14 and the figures.	1 - 41

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/00788

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
AU	57853/80	CA	1137353	DE	3014975
		GB	2047066	NL	8002290
				FR	2454275
				NZ	193472
AU	71549/91	CA	2073855	DE	69131861
		JP	5503847	US	5958770
				EP	515386
				WO	91/10743
AU	35454/00	WO	00/61153	CA	2369272
				EP	1181022
END OF ANNEX					